---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-072556"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2022-11-15T23:59:59+00:00"
generated_at: "2026-06-21T18:27:04.984432+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adial Pharma Q3 net loss narrows to $3.1M; CEO promoted, AD04 regulatory submission in progress

## Summary
- Net loss of $3.1M ($0.12/shr) vs $4.3M ($0.22/shr) in Q3 2021.
- Cash and equivalents $5.8M as of Sep 30, 2022, from $6.1M at Dec 31, 2021.
- R&D expenses fell 26% to $1.3M; G&A expenses fell 18% to $1.9M vs year-ago quarter.
- Cary Claiborne promoted to President and CEO; William Stilley named CEO of Purnovate subsidiary.
- Advancing AD04 ONWARD Phase 3 results to regulators; active partnership discussions for AD04 and Purnovate compounds.

## SEC filing metadata
- accession: 0001213900-22-072556
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2022-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390022072556/0001213900-22-072556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390022072556/ea168662-8k_adialpharm.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-072556
- JSON: https://secwatch.observer/filing/0001213900-22-072556.json
- Plain text: https://secwatch.observer/filing/0001213900-22-072556.txt

## Key facts
- Earnings Releases
  ADIAL PHARMACEUTICALS, INC. reported third quarter of 2022 results: net income $3.1 million, EPS $0.12.
  - Period: third quarter of 2022
  - Net income: $3.1 million
  - EPS: $0.12
  - Result: reported results
  source text: Net Loss was $3.1 million for the third quarter of 2022 as compared to a net loss of $4.3 million in the third quarter of 2021. Net loss per share for the third quarter of 2022 was $0.12, compared to a net loss of $0.22 per share for the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390022072556/0001213900-22-072556-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.